Literature DB >> 10161379

Using filgrastim efficiently.

G Dranitsaris.   

Abstract

Mesh:

Substances:

Year:  1996        PMID: 10161379     DOI: 10.2165/00019053-199609050-00009

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

Review 1.  From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever.

Authors:  W T Hughes; D Armstrong; G P Bodey; R Feld; G L Mandell; J D Meyers; P A Pizzo; S C Schimpff; J L Shenep; J C Wade
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

2.  Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.

Authors:  J E Frampton; D Faulds
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

3.  Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial.

Authors:  I A Malik; W A Khan; M Karim; Z Aziz; M A Khan
Journal:  Am J Med       Date:  1995-03       Impact factor: 4.965

4.  Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.

Authors:  E B Rubenstein; K Rolston; R S Benjamin; J Loewy; C Escalante; E Manzullo; P Hughes; B Moreland; A Fender; K Kennedy
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

5.  The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.

Authors:  F Silvestri; R Fanin; M Velisig; G Barillari; L Virgolini; F Zaja; D Russo; M Baccarani
Journal:  Tumori       Date:  1994-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.